MedTrace Logo

Genetics of QT Prolongation With Antiarrhythmics

NCT02439658 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-04-04

No results posted yet for this study

Summary

To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.

Conditions

  • Long QT Syndrome
  • Drug Toxicity

Interventions

DRUG

Dofetilide and/or sotalol

This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • The Cleveland Clinic

    collaborator OTHER

  • University of Colorado, Denver

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Christopher Newton-Cheh, MD, MPH · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2022-12-31
Completion
2023-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02439658 on ClinicalTrials.gov